Company intelligence / Profile preview
Addimmune
Rockville, Maryland, United Statesaddimmune.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
Phase 1 trial of AGT103-T (single-infusion gene therapy) showed positive safety in all seven patients: 100% engraftment, expansion, and reactivity of modified T cells to HIV; no serious adverse events or cell rejection at 180 days. Follow-on studies showed immune responses and viral suppression in several participants, aiming for a one-time functional cure freeing patients from lifelong antiretroviral therapy. Finalized results pending peer review publication.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Gene therapyCell therapy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
SPAC merger with 10X Capital Venture Acquisition Corp. IIIEquity facility agreement with Cantor Fitzgerald
Beyond the preview
Go deeper on Addimmune.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Addimmune.